stoxline Quote Chart Rank Option Currency Glossary
  
Daxor Corporation (DXR)
8.189  -0.291 (-3.43%)    03-18 16:00
Open: 8.25
High: 8.25
Volume: 2,329
  
Pre. Close: 8.48
Low: 8.189
Market Cap: 39(M)
Technical analysis
2024-03-18 4:43:36 PM
Short term     
Mid term     
Targets 6-month :  10.38 1-year :  12.12
Resists First :  8.89 Second :  10.38
Pivot price 7.9
Supports First :  7.83 Second :  7.19
MAs MA(5) :  8.37 MA(20) :  8.04
MA(100) :  8.41 MA(250) :  9.4
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  81.6 D(3) :  83.3
RSI RSI(14): 49.2
52-week High :  13.13 Low :  7.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ DXR ] has closed below upper band by 31.6%. Bollinger Bands are 1.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.26 - 8.3 8.3 - 8.34
Low: 8.09 - 8.14 8.14 - 8.17
Close: 8.12 - 8.19 8.19 - 8.25
Company Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Headline News

Mon, 18 Mar 2024
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewswire

Mon, 18 Mar 2024
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of ... - GlobeNewswire

Mon, 18 Mar 2024
(DXR) Investment Analysis - Stock Traders Daily.com

Fri, 15 Mar 2024
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com

Mon, 11 Mar 2024
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base - Marketscreener.com

Mon, 11 Mar 2024
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base - Yahoo Canada Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 2.06e+006 (%)
Held by Institutions 57 (%)
Shares Short 7 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 2 %
Operating Margin 228.9 %
Return on Assets (ttm) -452.6 %
Return on Equity (ttm) -2.4 %
Qtrly Rev. Growth 177370 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.64
Stock Dividends
Dividend 0
Forward Dividend 10780
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android